IRVING, Texas--( BUSINESS WIRE )--Blackhawk Claims Service, an innovative of market leading third-party administrator (TPA), announced today it has partnered with Blue Genes, an app-based tool that allows patients and providers to personalize medication plans based on drug-to-drug interactions and genetic compatibility. Providing members with an accurate and in-depth understanding of how their genetics interact with their prescriptions results in less risk of adverse drug reactions and reduced c

Abiomed — bought by Johnson & Johnson for $16.6 billion last year — recalled 466 affected devices. It distributed these Impella 5.5 with SmartAssist devices between Sept. 28, 2021, and March 6, 2023. The company initiated its recall on April 17. 2023. Impella 5.5 with SmartAssist supports the pumping chambers of the heart for up to 14 days when cardiogenic shock occurs less than 48 hours after a severe heart attack, open-heart surgery or when the heart functions poorly due to cardiomyopathy. Abi

HONORING ARTIST + ACTIVIST NAN GOLDIN; HOSTED BY SHARON STONE THE NEW EVENT IS A REIMAGINING OF THE BAILEY HOUSE GALA + AUCTION, A COLLECTION OF ART AND ONE-OF-A KIND EXPERIENCES SET FOR AUCTION IN SUPPORT OF BAILEY HOUSE JUNE 14 @ THE BOWERY HOTEL NEW YORK, June 5, 2023 /PRNewswire/ -- Bailey House, a leading community based organization dedicated to providing housing and supportive services for people living with HIV/AIDS and other chronic illness, will host the inaugural ART HOUSE benef

TYSONS, Va.--( BUSINESS WIRE )-- Zephyr AI, Inc. (“Zephyr AI”), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients’ lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. “At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhe

SOMERSET, N.J.--( BUSINESS WIRE )--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that results from the Phase 3 CARTITUDE-4 study showed that, at a median follow up of 16 months, cilta-cel reduced the risk of disease progression or death by 74 percent compared to standard of care regimens in adult patients with multiple myeloma who have rec

The monoclonal antibodies pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis. LAS VEGAS, June 5, 2023 /PRNewswire/ -- DelveInsight's ' Monoclonal Antibodies Competitive Landscape – 2023 ' report provides comprehensive global coverage of available, marketed, and pipeline monoclonal antibodies in various stages of clinical development, major pharmaceutical companies working to advance the

At 16-months median follow-up, CARVYKTI® significantly improved progression-free survival compared to two standard treatments1 Data presented at the 2023 ASCO and EHA Annual Meetings and published in The New England Journal of Medicine CHICAGO, June 5, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that results from the Phase 3 CARTITUDE-4 study showed CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) reduced the risk of disease progression or death

MOUNT ROYAL, N.J.--( BUSINESS WIRE )-- The American Headache Society® (AHS) , a professional society of healthcare providers dedicated to the study and treatment of headache and face pain, will host its 2023 Annual Scientific Meeting on June 15-18. Attendees can participate in person or virtually, gaining practical, clinical, evidence-based information on the diagnosis, management, and treatment of headache disorders. “It is an exciting time in the field of headache medicine. It is gratifying to

France-based Biocorp specializes in the design, development and manufacturing of delivery systems and medical devices. Its offerings include Mallya, a Bluetooth-enabled smart add-on device for pen injectors. Mallya, a smart sensor, attaches directly to insulin pen injectors to make them connected devices. It automatically collects and records key treatment information and transmits it to a dedicated digital application. That data includes selected insulin units, date and time of injection. The F

如何看待2023年即将过去的上半年集采的进展？可能很多业内同仁五味杂陈。是的，上半年药品集采，已经不能简单用集采来形容，。伴随着价格调整的种种变化，有时候，我们真的不得不感叹看山也是山、看水也是水的那种视野与境界。药品集采变化的趋势，再一次从原本短兵相接的“拉锯战”走到了灵活变化的“运动战场”。2019年11月，国务院深化医药卫生体制改革领导小组印发的《关于以药品集中采购和使用为突破口 进一步深化医药卫生体制改革的若干政策措施》（国医改发〔2019〕3号）正式下发，笔者当时看到相关内容的第一反应就是，未来的三至五年将是药品集中采购开展的关键时刻。主要判断依据是2019年地方带量采购尚未成型，2020年仍然处于探索起步阶段，2021年是启动之年，2022至2024是集采真正发力的阶段。，才是全国药品集采纷纷落地的主要年份。来源：PDB药物综合数据库 中国医药工业信息中心通过PDB药物综合数据库可以看出，从2019年到2022年，全国整体样本市场销售金额其实是在持续下降的，从2019年的2551亿、2020年的2213亿、2021年的2356亿再到2022年的2205亿，这四年，伴随着药品